Fady Ibraham Malik Sells 2,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $48.06, for a total value of $96,120.00. Following the completion of the sale, the executive vice president now owns 116,071 shares in the company, valued at approximately $5,578,372.26. This represents a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Fady Ibraham Malik also recently made the following trade(s):

• On Tuesday, January 21st, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The shares were sold at an average price of $45.92, for a total value of $91,840.00.
• On Tuesday, January 7th, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The stock was sold at an average price of $49.32, for a total value of $98,640.00.
• On Tuesday, December 10th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The stock was sold at an average price of $50.64, for a total value of $369,672.00.
• On Tuesday, November 26th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The stock was sold at an average price of $50.16, for a total value of $366,168.00.
• On Tuesday, November 12th, Fady Ibraham Malik sold 6,342 shares of Cytokinetics stock. The stock was sold at an average price of $58.48, for a total value of $370,880.16.

Cytokinetics Trading Up 1.5 %

Shares of Cytokinetics stock traded up $0.73 on Tuesday, hitting $49.20. 1,319,037 shares of the company’s stock traded hands, compared to its average volume of 1,171,056. The firm’s 50-day moving average price is $48.72 and its two-hundred day moving average price is $52.62. The stock has a market capitalization of $5.81 billion, a PE ratio of -9.14 and a beta of 0.83. Cytokinetics, Incorporated has a one year low of $44.49 and a one year high of $81.36. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.09). The company had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $1.21 million. The company’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.35) earnings per share. On average, research analysts expect that Cytokinetics, Incorporated will post -5.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Cytokinetics

Large investors have recently modified their holdings of the business. Centricity Wealth Management LLC acquired a new position in shares of Cytokinetics during the 4th quarter worth about $29,000. UMB Bank n.a. lifted its stake in Cytokinetics by 65.6% in the 3rd quarter. UMB Bank n.a. now owns 601 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 238 shares during the last quarter. Blue Trust Inc. lifted its stake in Cytokinetics by 225.9% in the 3rd quarter. Blue Trust Inc. now owns 981 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 680 shares during the last quarter. Values First Advisors Inc. acquired a new stake in Cytokinetics in the 3rd quarter valued at about $54,000. Finally, R Squared Ltd acquired a new stake in Cytokinetics in the 4th quarter valued at about $133,000.

Analyst Ratings Changes

Several brokerages have recently commented on CYTK. Mizuho raised their target price on Cytokinetics from $99.00 to $103.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. JMP Securities reiterated a “market outperform” rating and set a $78.00 price objective on shares of Cytokinetics in a report on Tuesday, January 14th. Stifel Nicolaus started coverage on Cytokinetics in a report on Wednesday, January 22nd. They set a “buy” rating and a $80.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Cytokinetics in a report on Friday, October 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $120.00 price target on shares of Cytokinetics in a research report on Tuesday, January 21st. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $82.79.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.